MAP2K7 and cancer: Given its dual role as both an EGFR modulator [88,89] and downstream effector in Ras/Raf/Mek/MAPK signaling [83], combinatorial targeting of TNS4 and EGFR represents a rational strategy for EGFR-dysregulated cancers.